Atlas Trials

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Clinical trial NCT00621452 · COMPLETED

Trial details

NCT number
NCT00621452
Sponsor
Fred Hutchinson Cancer Center
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
B-cell Chronic Lymphocytic LeukemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaSplenic Marginal Zone LymphomaWaldenström Macroglobulinemia
Start date
2007-08-01
Primary completion
2014-01-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.